In Annapolis, Maryland, lawmakers are considering a proposal to strip state tax breaks from prescription drug commercials and redirect the savings into Medicaid and health insurance marketplace subsidies. Backers say the shift could free roughly $23 to $24 million a year. The plan would bar companies from deducting certain direct-to-consumer advertising costs on their state corporate income tax returns, and sponsors want that money steered into Medicaid eligibility operations and premium assistance. Opponents say the move singles out drugmakers and could face constitutional challenges.
What the bill would do
According to the Maryland General Assembly, House Bill 484 would require corporations to add back, for state corporate income tax purposes, expenses they can currently deduct under federal law for direct-to-consumer advertising of covered prescription drugs. The bill lists Delegate Natalie Ziegler as the primary sponsor and would take effect July 1, if enacted. Supporters have also filed a Senate companion, SB 987, with comparable language.
Where the money would go
Analysts and advocates say the revenue at stake is not pocket change. Public Citizen estimates the change could generate roughly $23 million a year under current assumptions about drug advertising spending, while noting that actual collections could land higher or lower. The group says the bills would earmark about $5 million annually for the Maryland Department of Health to strengthen Medicaid eligibility operations, with the remaining funds directed to premium subsidies on the state exchange. The League of Women Voters offered similar testimony in support of HB 484, arguing that the shift would generate revenue for programs that help keep Marylanders insured.
Supporters and opponents
Supporters, including patient advocates, consumer groups, and some lawmakers, frame the proposal as a simple rerouting of an existing tax break into health coverage. They argue that if taxpayers are effectively subsidizing part of the drug industry’s ad budget, the money might as well help residents stay insured. Horizon Foundation CEO Nikki Highsmith warned that "160,000 Marylanders — 160,000 enrollees, many of (whom) are Black and brown neighbors — will lose coverage" if the legislature does not act, as reported by WBAL NewsRadio.
Industry trade groups are not buying it. In committee testimony, a representative for the Pharmaceutical Research and Manufacturers of America called the proposal "punitive" and argued that it unfairly singles out drugmakers for different tax treatment from other advertisers.
Legal questions ahead
Legal analysts warn that targeting only prescription drug advertising could be a constitutional tightrope. A state law that withdraws a tax benefit solely for drug ads is likely to draw heightened First Amendment scrutiny because it focuses on particular speakers and specific content. As explained by legal commentators at Brownstein Hyatt Farber Schreck, writing on JDSupra, Supreme Court precedents such as Sorrell and Western States require courts to examine whether a speech-focused restriction directly advances a substantial government interest and is no more extensive than necessary. That test could make the measures vulnerable to constitutional challenge, even if lawmakers emphasize cost control and coverage goals.
What happens next
The House bill received a hearing in the Ways and Means Committee on Feb. 12, and the Senate companion was scheduled for a Budget and Taxation Committee hearing on March 11, according to Maryland General Assembly records. If either chamber advances the language to final passage and the governor signs it, the changes would take effect July 1 and apply to tax years beginning after Dec. 31, 2025. Advocates and opponents alike say the coming weeks will hinge on fiscal estimates, committee votes, and the looming question of whether a court challenge materializes.
